How does five factor score perform for contemporary PAN? 447 pts -> 36 deaths Infection > vasculitis for mortality FFS = 1 trends but NOT significantly associated with mortality FFS 2 or higher very associated Prediction enhanced w/ other factors #Abst1140 @RheumNow #ACR26 https://t.co/O9AJYm4iy8

As IL-17 gets more discussed in persistent ICI-IA, IL-17i will be discussed as therapy 8 cases @MassGenBrigham, 3 had ICI-colitis (one fatal) limited safe experience in literature & irAEs do clump together but IL-17 important in gut barrier one to watch ABST1675 #ACR26 @RheumNow https://t.co/Er3xSOc12m

CAR-T in SLE 2026 -Autologous CART: likely to achieve target faster (shorter time for SLEDAI/DORIS) -CD19-vs dual target (BCMA): no significant difference on SLEDAI -Pt w/ LN at baseline had steeper decline on SLEDAI -SAFETY: 64% of pts had CRS manageable (low grade) 95% of https://t.co/XyMOeoSpPL

ACR 2026 – Biotech and Mid-Size Companies Bet on Novel Mechanisms ACR Convergence 2026 is crowded with first-in-class mechanisms: an oral IL-23 receptor peptide, FcRn blockade, a JAK head-to-head and a wave of cell depletion therapies. https://t.co/hhUX2ZXJlp https://t.co/rvpzdh56H7

With weight loss: ↓ leptin, ↑ appetite, ↓ energy expenditure But leptin therapy ineffective for weight loss Leptin --> pro-inflammatory --> higher in PsA --> correlate with disease acitivty and duration @RheumNow #ACR26 https://t.co/2gUjaMGzxM

SjD management: what is new? -Current therapies with low efficacy and no strong data. -Define target population: Important on treatment response What is new: -Ianalumab: B cell depletion. -Telitacicept: dual target Blyss+APRIL phase 3 showed promising results on both activity and https://t.co/ccJFr8Gb5t

EULAR/ACR 2025 arthralgia risk score validated in real-world cohort: AUC 0.80 Argentina, n=1,803, 10.3% RA at 12 mo Low risk: 6% RA (92% of pts) Intermediate: 45% High: 93% (n=27) US PD added 0.015 to AUC. Triage works without imaging. @RheumNow #ACR26 Abstr#1837 https://t.co/fztG7PrCJb

Another blow to the physical exam... Pulse exam NOT sufficient for evaluation of TAK lesions - pulse loss correlates with arm/neck lesion - pulse loss inconsistent for leg lesion - MANY silent lesions w/o exam change Serial imaging remains standard #Abst1126 @RheumNow #ACR26 https://t.co/U9a0muql5Q

CD40 modulation: unfamiliar but promising MOA in rheumatology esp re; SjD CD40 mediates crosstalk between T + B cells Dazodalibep (DAZ) and Iscalimab currently in development. DAZ SjD trial dropping as late breaking abstract LB22 on Wed 11/11 #ACR26 @RheumNow https://t.co/hzIedKV3kE

Should we triage TAK tx by age? 2 TAK cohorts TNFi responders: YOUNGER - mean age 23 Toci responders: OLDER - mean age 35 How does age change disease pathophys and are older patients closer to a GCA-spectrum disease? Potentially practice changing #ACRbest @RheumNow #Abst1124 https://t.co/JxAsRm8Q4M

Can we add JAKi to our TAK arsenal? Systemic review/meta-analysis of JAK treated TAK patients: Overall response rate - 86% at Mo 6 - 76.6% at Mo 12 Hugely encouraging # but need more info about specifics of their endpoint #Abst1123 @RheumNow #ACR26 https://t.co/u9Sas0DBMe